GDC-0276 是一种有效的、选择性的、可逆的口服活性 NaV1.7 抑制剂,其 IC50 值为 0.4 nM。GDC-0276 耐受性良好,显现良好的药代动力学特征。GDC-0276 有潜力用于治疗疼痛以及解决现有止痛药物缺陷,如成瘾和脱靶副作用的相关研究。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC50 value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects[1].
[1]. Rothenberg ME, et al. Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study i [2]. Steven J. McKerrall, et al. Nav1.7 inhibitors for the treatment of chronic pain. Bioorganic & Medicinal Chemistry Letters (2018) [3]. Takahashi RH,et al.Unequal Absorption of Radiolabeled and Nonradiolabeled Drug from the Oral Dose Leads to Incorrect Estimates of Drug Absorption and Circulating Metabolites in a Mass Balance Study.Drug Metab Lett. 2019;13(1):37-44.
Quinupristin-Dalfopristin Complex (mesylate)
¥2560.00 ¥3200.00
Tankyrase Inhibitors (TNKS) 49
¥1320.00 ¥1650.00
没有评价数据